Stockscreener 앱 받기
2.04
1.49%
0.03
전일 마감가:
$2.01
열려 있는:
$2
하루 거래량:
29,948
Relative Volume:
1.22
시가총액:
$22.17M
수익:
$56.60M
순이익/손실:
$-34.12M
주가수익비율:
-0.445
EPS:
-4.5844
순현금흐름:
$-1.36M
1주 성능:
+0.74%
1개월 성능:
+3.55%
6개월 성능:
-20.93%
1년 성능:
-12.07%
1일 변동 폭
$1.96
$2.14
1주일 범위
$1.9362
$2.14
52주 변동 폭
$1.80
$3.065
Aytu Biopharma Inc Stock (AYTU) Company Profile
명칭
Aytu Biopharma Inc
전화
(720) 437-6580
주소
7900 E. UNION AVENUE, DENVER
Compare AYTU vs TAK, TEVA, HLN, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AYTU
Aytu Biopharma Inc
|
2.04 | 22.17M | 56.60M | -34.12M | -1.36M | -4.5844 |
TAK
Takeda Pharmaceutical Co Adr
|
19.67 | 62.84B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
41.50 | 48.40B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
10.13 | 44.55B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
79.38 | 32.80B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
533.12 | 22.87B | 3.17B | 1.29B | 1.01B | 27.09 |
Aytu Biopharma Inc Stock (AYTU) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-01 | 개시 | Lake Street | Buy |
| 2025-06-30 | 개시 | Ascendiant Capital Markets | Buy |
| 2021-03-30 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-05-29 | 개시 | H.C. Wainwright | Buy |
Aytu Biopharma Inc 주식(AYTU)의 최신 뉴스
Aytu BioPharma, Inc. Stock Price Today | AYTU Live Chart & News - Traders Union
Elite Pharmaceuticals vs. Aytu: Which CNS Stock Is the Better Buy? - Zacks Investment Research
Aytu BioPharma (NasdaqCM:AYTU) Stock Forecast & Analyst Predictions - Simply Wall Street
Latigo Biotherapeutics, Inc. Common Stock (LTGO) Earnings Reports & Dates - FXEmpire
AYTU|Aytu Biopharma Inc|Price:2.230|Chg%:+0.105 - TradingKey
Aytu BioPharma Narrows Fiscal 2026 Loss to $14.3 Million as EXXUA Debuts - Minichart
Aytu BioPharma, Inc. (AYTU) Reports Q4 Loss, Beats Revenue Estimates - Zacks Investment Research
EXXUA prescriptions jump as Aytu BioPharma (AYTU) posts Q4 and full-year results - Stock Titan
A depression drug generated $3.9 million in its first full quarter - Stock Titan
When Will Aytu BioPharma, Inc. (NASDAQ:AYTU) Turn A Profit? - simplywall.st
AYTU Q2 2026 Earnings: Loss Per Share Misses by 1.88% as Stock Holds UpDividend Cut Risk - vinanet.vn
AYTU | AYTU BioPharma, Inc. Common FinancialsRevenue Breakdown - Quiver Quantitative
Aytu (AYTU) Q2 2026 Earnings: EPS Misses Its Estimate; Closing Move: The Market Reaction Is Muted in the Current UpdatePerformance Review - vinanet.vn
Aytu BioPharma (AYTU) investor and foundation each report 4.99% beneficial stake - Stock Titan
Aytu BioPharma (AYTU) Slips 1.7% to $2.36 as Biotech Volatility PersistsRisk Parity Rebalance - vinanet.vn
Aytu BioPharma (AYTU) Slips 1.7% to $2.36 as Biotech Volatility PersistsZigzag Correction - dars.gov.et
AYTU Q2 2026 Earnings: Narrow EPS Miss Slightly Wider Than Expected, Shares Rise 1.69%Earnings Expansion Phase - vinanet.vn
Aytu Biopharma Inc (AYTU) Stock News Today - TradingKey
Aytu BioPharma, Inc. (0A8M.L) valuation measures and financial statistics - Yahoo Finance Australia
Aytu Biopharma Inc (AYTU) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CNSY Stock Price and Chart — NASDAQ:CNSY - tradingview.com
Aytu BioPharma (AYTU) Climbs 3.72% to $2.23 — Approaching Key ResistanceBreadth Thrust - vinanet.vn
Aytu BioScience Inc (0A8M) Q2 2026 Earnings ReportResults, Call & Slides - TipRanks
Aytu Biopharma Inc (AYTU) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Aytu Biopharma Inc (AYTU) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Aytu BioPharma Market Sentiment - Benzinga España
Aytu Biopharma Inc (AYTU) Cash Flow - TradingKey
Aytu Biopharma Inc (AYTU) Balance Sheet - TradingKey
AYTU|Aytu Biopharma Inc|Price:2.107|Chg%:+0.046 - TradingKey
AYTU|Aytu Biopharma Inc|Price:2.160| - TradingKey
Aytu Biopharma Inc (AYTU) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Aytu Biopharma Inc (AYTU) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Aytu Biopharma Inc (AYTU) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Aytu Biopharma Inc (AYTU) Income Statement - TradingKey
AYTU Q2 2026 Earnings: EPS Misses Estimates by Nearly 2%, Stock Holds SteadyProfit Announcement - vinanet.vn
Aytu BioPharma, Inc. Revenue Breakdown – NASDAQ:AYTU - TradingView
AYTU Q2 2026 Earnings: EPS Slightly Misses Estimates with Minimal SurprisePerformance Review - vinanet.vn
AYTU Q2 2026 Earnings: EPS Misses Estimates Amid Challenging QuarterCore Business Growth - vinanet.vn
Aytu BioPharma (AYTU) Edges Higher as Stock Tests Key ResistanceOvernight Profile - vinanet.vn
AYTU Q2 2026 Earnings: EPS Misses Estimates Amid No Revenue; Stock Edges HigherCapex Guidance - vinanet.vn
AYTU Q2 2026 Earnings: EPS Misses Consensus, Stock Falls SlightlyRevenue Guidance Update - vinanet.vn
AYTU Q2 2026 Earnings: EPS Misses Estimates, Stock DeclinesNet Income Trends - vinanet.vn
New Strong Sell Stocks for July 16th - Yahoo Finance
AYTU Q2 2026 Earnings: EPS Misses Estimates, Shares Edge HigherPost-Earnings Drift - vinanet.vn
AYTU Q2 2026 Earnings: EPS Misses Estimates Amid Narrow Loss; Stock Edges HigherPost-Earnings Drift - vinanet.vn
Aytu BioPharma (AYTU) Edges Higher, Testing Key Resistance LevelsGap Fill Strategy - dars.gov.et
Aytu BioPharma (AYTU) Edges Higher, Testing Key Resistance LevelsBollinger Walk - DonanımHaber
Aytu BioPharma (AYTU) Edges Higher, Testing Key Resistance LevelsRVOL Breakout - dars.gov.et
AYTU Q2 2026 Earnings: EPS Miss Slightly Wider Than Expected; Stock Rises 2.74% Amid Strategic ReviewEarnings Beat Streak - dars.gov.et
AYTU Q2 2026 Earnings: EPS Misses Estimates Slightly, Stock Edges HigherNet Profit Margin - dars.gov.et
Aytu Biopharma Inc (AYTU) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.55%
5.96%
자본화:
|
볼륨(24시간):